{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:52:54Z","timestamp":1762231974073,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443222405"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015230","name":"Fondation Cancer","doi-asserted-by":"publisher","award":["C20\/BM\/14592342","C20\/BM\/14582635"],"award-info":[{"award-number":["C20\/BM\/14592342","C20\/BM\/14582635"]}],"id":[{"id":"10.13039\/100015230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.mcb.2024.03.012","type":"book-chapter","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:53:40Z","timestamp":1713455620000},"page":"109-129","source":"Crossref","is-referenced-by-count":1,"title":["E\u03bc-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia"],"prefix":"10.1016","member":"78","reference":[{"issue":"110","key":"10.1016\/bs.mcb.2024.03.012_bb0010","doi-asserted-by":"crossref","DOI":"10.3791\/53936","article-title":"Murine hind limb long bone dissection and bone marrow isolation","author":"Amend","year":"2016","journal-title":"Journal of Visualized Experiments"},{"issue":"5","key":"10.1016\/bs.mcb.2024.03.012_bb0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2019.242016","article-title":"Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia","volume":"106","author":"Arruga","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/bs.mcb.2024.03.012_bb0020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/leu.2012.268","article-title":"Xenograft models of chronic lymphocytic leukemia: Problems, pitfalls and future directions","volume":"27","author":"Bertilaccio","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.mcb.2024.03.012_bb0025","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/bs.mcb.2024.03.012_bb0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: From genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.419","article-title":"TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia","volume":"7","author":"Bresin","year":"2016","journal-title":"Cell Death & Disease"},{"issue":"8","key":"10.1016\/bs.mcb.2024.03.012_bb0040","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment\u2014From chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"12","key":"10.1016\/bs.mcb.2024.03.012_bb0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.mcb.2024.03.012_bb0050","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41419-022-05178-w","article-title":"GSK3\u03b2 is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL","volume":"13","author":"De Falco","year":"2022","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0055","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/s41467-021-23752-2","article-title":"Targeted PI3K\/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia","volume":"12","author":"Ecker","year":"2021","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2643-3230.BCD-22-0029","article-title":"Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses","volume":"4","author":"Gargiulo","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/bs.mcb.2024.03.012_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578176","article-title":"Method for the analysis of the tumor microenvironment by mass cytometry: Application to chronic lymphocytic leukemia","volume":"11","author":"Gonder","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"18","key":"10.1016\/bs.mcb.2024.03.012_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184518","article-title":"The tumor microenvironment-dependent transcription factors AHR and HIF-1\u03b1 are dispensable for Leukemogenesis in the E\u03bc-TCL1 mouse model of chronic lymphocytic leukemia","volume":"13","author":"Gonder","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/bs.mcb.2024.03.012_bb0075","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"10.1016\/bs.mcb.2024.03.012_bb0080","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/bloodadvances.2020003795","article-title":"CD4+ T cells sustain aggressive chronic lymphocytic leukemia in E\u03bc-TCL1 mice through a CD40L-independent mechanism","volume":"5","author":"Grioni","year":"2021","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/bs.mcb.2024.03.012_bb0085","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.mcb.2024.03.012_bb0090","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1016\/bs.mcb.2024.03.012_bb0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.mcb.2024.03.012_bb0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.leu.2404017","article-title":"TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state","volume":"20","author":"Herling","year":"2006","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/bs.mcb.2024.03.012_bb0105","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2009-03-208256","article-title":"High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia","volume":"114","author":"Herling","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.mcb.2024.03.012_bb0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2021011516","article-title":"Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia","volume":"139","author":"Jebaraj","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.mcb.2024.03.012_bb0115","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/bs.mcb.2024.03.012_bb0120","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/bs.mcb.2024.03.012_bb0125","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nature Reviews. Disease Primers"},{"issue":"11","key":"10.1016\/bs.mcb.2024.03.012_bb0130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nature Genetics"},{"issue":"26","key":"10.1016\/bs.mcb.2024.03.012_bb0135","first-page":"3166","article-title":"Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL","volume":"141","author":"Largeot","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/bs.mcb.2024.03.012_bb0140","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.1631","article-title":"Immune cell isolation from mouse femur bone marrow","volume":"5","author":"Liu","year":"2015","journal-title":"Bio-Protocol"},{"issue":"22","key":"10.1016\/bs.mcb.2024.03.012_bb0145","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo","volume":"140","author":"Martines","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","article-title":"Restoration of the immune function as a complementary strategy to treat chronic lymphocytic leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"2","key":"10.1016\/bs.mcb.2024.03.012_bb0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41375-021-01381-4","article-title":"Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients","volume":"36","author":"\u00d6zt\u00fcrk","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.mcb.2024.03.012_bb0160","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41375-018-0332-5","article-title":"Rejection of adoptively transferred E\u03bc-TCL1 chronic lymphocytic leukemia cells in C57BL\/6 substrains or knockout mouse lines","volume":"33","author":"\u00d6zt\u00fcrk","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2024.03.012_bb0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fonc.2018.00317","article-title":"T-cell leukemia\/lymphoma 1 (TCL1): An oncogene regulating multiple signaling pathways","volume":"8","author":"Paduano","year":"2018","journal-title":"Frontiers in Oncology"},{"issue":"11","key":"10.1016\/bs.mcb.2024.03.012_bb0170","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3324\/haematol.2022.282474","article-title":"Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia","volume":"108","author":"Pagano","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.mcb.2024.03.012_bb0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccr.2004.08.033","article-title":"APRIL promotes B-1 cell-associated neoplasm","volume":"6","author":"Planelles","year":"2004","journal-title":"Cancer Cell"},{"issue":"35","key":"10.1016\/bs.mcb.2024.03.012_bb0180","doi-asserted-by":"crossref","DOI":"10.3791\/1488","article-title":"Isolation of mouse peritoneal cavity cells","author":"Ray","year":"2010","journal-title":"Journal of Visualized Experiments"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.16316","article-title":"TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E\u03bc-TCL1 mice","volume":"189","author":"Roessner","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1016\/bs.mcb.2024.03.012_bb0190","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2014-05-577122","article-title":"Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy","volume":"124","author":"Simonetti","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.mcb.2024.03.012_bb0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Sk\u00e5nland","year":"2021","journal-title":"Blood Advances"},{"issue":"19","key":"10.1016\/bs.mcb.2024.03.012_bb0200","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"Ten Hacken","year":"2018","journal-title":"JCI Insight"},{"issue":"25","key":"10.1016\/bs.mcb.2024.03.012_bb0205","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2021011993","article-title":"Understanding CLL biology through mouse models of human genetics","volume":"138","author":"Ten Hacken","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.mcb.2024.03.012_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in E\u03bc-TCL1 transgenic mice","volume":"111","author":"Widhopf","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.mcb.2024.03.012_bb0215","article-title":"High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia","volume":"7","author":"Wierz","year":"2018","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/bs.mcb.2024.03.012_bb0220","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.3324\/haematol.2017.175349","article-title":"The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model","volume":"103","author":"Wierz","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/bs.mcb.2024.03.012_bb0225","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.mcb.2024.03.012_bb0230","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","article-title":"Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development","volume":"33","author":"Zaborsky","year":"2019","journal-title":"Leukemia"},{"issue":"47","key":"10.1016\/bs.mcb.2024.03.012_bb0235","doi-asserted-by":"crossref","first-page":"16600","DOI":"10.1073\/pnas.0407541101","article-title":"TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma\/chronic lymphocytic leukemia in transgenic mice","volume":"101","author":"Zapata","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"}],"container-title":["Methods in Cell Biology","Animal Models of Disease - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X2400102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X2400102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:48:17Z","timestamp":1762231697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X2400102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443222405"],"references-count":46,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2024.03.012","relation":{},"ISSN":["0091-679X"],"issn-type":[{"type":"print","value":"0091-679X"}],"subject":[],"published":{"date-parts":[[2024]]}}}